Ecological genetics of freshwater fish: a short review of the genotype–phenotype connection by Vidal, O., García–Marín, J. L.

Get full text

SNP identification and validation in two invasive species: zebra mussel (Dreissena polymorpha) and Asian clam (Corbicula fluminea) by Peñarrubia, L., Viñas, J., Sanz, N., Smith, B. L., Alvarado Bremer, J. R., Pla, C., Vidal, O.

Get full text

Evaluating Sealing Efficiency of Caprocks for CO2 Storage: an Overview of the Geocarbone-Integrity Program and Results Évaluation de l’intégrité des couvertures d’un stockage de C... by Fleury M., Pironon J., Le Nindre Y.M., Bildstein O., Berne P., Lagneau V., Broseta D., Pichery T., Fillacier S., Lescanne M., Vidal O.

Get full text

Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+ by Govindan, R, Dols, MC, Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Vidal, O, Stewart, D, Ardizoni, A, Weaver, J, Wolfsteiner, M, Reck, M, Talbot, D, Morgensztern, D, Ong, TJ

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer by Ponce Aix, S, Talbot, D, Ramaswamy, G, Cobo, M, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Jin Ong, T, Morgensztern, D

Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+ by Talbot, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Morgensztern, D, Ong, TJ

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+) by Morgensztern, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Talbot, D, Ong, TJ

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer... by Morgensztern, D, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, CR, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Fasola, G, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Talbot, DC, Jin Ong, T, Govindan, R, On Behalf Of The Abound L Investigators